PT Kalbe Farma Tbk shares traded broadly stable on the Indonesia Stock Exchange on 06/02/2026 as investors continued to digest the company’s recent 2025 earnings disclosure and cash dividend, keeping focus on the Indonesian pharmaceutical group’s domestic market dynamics.
PT Kalbe Farma Tbk shares were little changed in Jakarta on 06/02/2026, with the stock trading around recent levels on the Indonesia Stock Exchange (IDX) as the Indonesian pharmaceutical group’s 2025 earnings report and dividend remain the main reference points for local investors.
The stock, which trades under the ticker KLBF in Indonesia, is one of the more liquid healthcare names on the IDX and is widely followed as a proxy for domestic demand for prescription drugs, over-the-counter medicines, and nutritional products in the company’s home market of Indonesia.
The company’s investor-relations materials and recent reporting highlight its focus on the Indonesian market, where it operates manufacturing facilities and a large distribution network, positioning it as a key player within the national healthcare and consumer health ecosystem, according to Kalbe’s disclosures as of 2025.
Market data providers tracking KLBF on the IDX show that the stock remains actively traded, underlining its status as a domestically important healthcare name; however, trading on 06/02/2026 did not show extraordinary price swings by local standards.
For Germany-based investors, PT Kalbe Farma Tbk can also be accessed via secondary quotations on German trading venues where available, typically in euros and with lower liquidity than on the Indonesia Stock Exchange, although the primary price discovery remains firmly centered on Jakarta.
Recent filings from PT Kalbe Farma Tbk’s investor relations and public reporting confirm that the group has continued to distribute cash dividends on the back of its 2025 financial performance, reflecting the company’s policy of sharing profits with shareholders subject to Indonesian regulatory approvals and shareholder meetings.
The company’s latest full-year and quarterly financial updates show that revenue and profit are driven primarily by prescription drugs, consumer health products, nutritionals, and distribution services, based on Kalbe’s published segment reporting for 2025.
PT Kalbe Farma Tbk’s 2025 earnings release, as summarized on its investor-relations pages and local financial news outlets, detailed the contribution of its principal business lines, with pharmaceuticals and consumer health products remaining key pillars of its Indonesian operations.
Dividend announcements linked to the 2025 financial year were reported in the Indonesian press and by the company itself, underlining that shareholder returns remain an important consideration for the board, alongside reinvestment into manufacturing capacity, research capabilities, and distribution infrastructure.
While specific price and volume statistics for 06/02/2026 depend on intraday trading data from the IDX, the general picture on the day was one of consolidation, as market participants continued to weigh macroeconomic conditions in Indonesia and the broader outlook for consumer spending on healthcare-related products.
The stock traded at a level in Indonesian rupiah that kept it comfortably within its 2025-2026 trading corridor, underlining that investors were not reacting to any new company-specific shock on 06/02/2026 but instead digesting existing information such as the 2025 earnings and dividend profile.
In the domestic context, the Indonesia Stock Exchange and local analysts typically classify PT Kalbe Farma Tbk within the healthcare or pharmaceutical sector, making it a reference name for any discussion about the Indonesian healthcare-equity universe.
Sector watchers in Indonesia note that the country’s demographics, rising healthcare awareness, and policy initiatives to expand access to medicines and healthcare services offer a structural backdrop for companies like PT Kalbe Farma Tbk, with the stock often mentioned in coverage of Indonesia’s healthcare sector.
As of: 06/02/2026
By the editorial team – specialized in equity coverage.
At a glance
- Name: Kalbe Farma
- Sector/industry: Pharmaceuticals and consumer health
- Headquarters/country: Jakarta, Indonesia
- Core markets: Indonesia and selected Southeast Asian markets
- Key revenue drivers: Prescription medicines, over-the-counter products, nutritionals, and distribution services
- Home exchange/listing venue: Indonesia Stock Exchange (KLBF)
- Trading currency: IDR
PT Kalbe Farma Tbk: core business model
PT Kalbe Farma Tbk operates as an integrated Indonesian healthcare group that develops, produces, and distributes pharmaceuticals, consumer health items, and nutritional products, with sales largely generated through its domestic-focused prescription, over-the-counter, nutrition, and distribution divisions.
Latest quarterly results for PT Kalbe Farma Tbk at a glance
The most recent quarterly report available from PT Kalbe Farma Tbk, covering a period within 2025, showed that the company continued to generate the bulk of its revenue from prescription pharmaceuticals and consumer health products, complemented by its nutrition and distribution segments as detailed in the company’s published financial statements for that year.
In that 2025 reporting period, management commentary emphasized the stability of domestic demand in Indonesia, noting that the mix between prescription drugs and consumer health products remained broadly in line with previous quarters, while the company continued to invest in production efficiency and product innovation according to its investor-relations communication.
Sentiment and reactions on PT Kalbe Farma Tbk
On social and video platforms, PT Kalbe Farma Tbk is often discussed in the context of Indonesia’s healthcare sector, domestic consumer trends, and the broader performance of the Jakarta market, with investors tracking both company-specific news and macroeconomic developments.
Conclusion
PT Kalbe Farma Tbk’s stock traded sideways on the Indonesia Stock Exchange on 06/02/2026, as investors continued to reference the company’s disclosed 2025 earnings and dividend policy rather than reacting to fresh company-specific headlines. The latest quarterly data from 2025 underline the group’s reliance on Indonesian demand for pharmaceuticals and consumer health items, with prescription and over-the-counter products at the center of its revenue mix. Against this backdrop, the stock remains a key barometer for market sentiment toward the Indonesian healthcare sector, even on quieter trading days without new news catalysts.
Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.